PDIA2: A Potential Drug Target and Biomarker for Rho GDP Dissociation Inhibitors

Target Name: PDIA2

NCBI ID: G64714

PDIA2

PDIA2: A Potential Drug Target and Biomarker for Rho GDP Dissociation Inhibitors

Introduction

Platelet-derived growth factors (PDGFs) are a family of cytokines that play a crucial role in tissue repair and regeneration. The PDGF signaling pathway is involved in many physiological processes, including cell proliferation, differentiation, and angiogenesis. One of the key regulators of PDGF signaling is the protein RhoA, which is a GTPase that regulates the dissociation of the GDP dimer from the protein RhoGTP. The RhoA/GDP complex is a critical target for many drugs, including small molecules, peptides, and antibodies. PDIA2, a novel protein that belongs to the RhoA/GDP complex, has recently been identified as a potential drug target and biomarker for Rho GDP dissociation inhibitors (RhoGTP inhibitors). In this article, we will discuss the biology of PDIA2 and its potential as a drug target and biomarker.

PDIA2: Structure and Function

PDIA2 is a 21-kDa protein that is expressed in many tissues, including platelets, neurons, and endothelial cells. It is a member of the RhoA/GDP complex and is involved in the regulation of PDGF signaling. PDIA2 functions as a GTPase to regulate the dissociation of the GDP dimer from RhoGTP. The RhoA/GDP complex is a protein-protein interaction that plays a central role in many cellular processes, including cell signaling, cytoskeletal organization, and vesicle trafficking. The RhoA/GDP complex is composed of two subunits: RhoA and GDP. RhoA is a 23kDa protein that contains a catalytic active center and several conserved transmembrane domains. GDP is a 26kDa protein that contains a GTP binding site and several conserved transmembrane domains. The GDP dimer is a binary structure that consists of two interconnected subunits. The N-terminus of the GDP dimer includes a 150 amino acid residue that is involved in the GTPase activity of RhoA. The C-terminus of the GDP dimer includes a 120 amino acid residue that is involved in the GTPase activity of RhoA.

PDIA2 is involved in the regulation of many cellular processes, including cell proliferation, differentiation, and angiogenesis. One of the key functions of PDIA2 is its role in the regulation of cell proliferation. PDIA2 has been shown to play a negative role in the regulation of cell proliferation in various cell types. For example, PDIA2 has been shown to inhibit the growth of human cancer cells in cell culture and in animal models of cancer. PDIA2 has also been shown to regulate the cell cycle in various cell types, including platelets and neurons.

PDIA2 is also involved in the regulation of cell differentiation and angiogenesis. For example, PDIA2 has also been shown to play a positive role in the regulation of platelet function in various physiological processes, including blood clotting. in the regulation of neuronal function and the development of neural circuits.

PDIA2 is also involved in the regulation of cellular signaling pathways. For example, PDIA2 has been shown to play a positive role in the regulation of the PI3K/Akt signaling pathway, which is involved in many cellular processes, including cell survival and angiogenesis. PDIA2 has also been shown to play a negative role in the regulation of the TGF-β signaling pathway, which is involved in cell growth, differentiation, and angiogenesis.

PDIA2 is also involved in the regulation of

Protein Name: Protein Disulfide Isomerase Family A Member 2

Functions: Acts as an intracellular estrogen-binding protein. May be involved in modulating cellular levels and biological functions of estrogens in the pancreas. May act as a chaperone that inhibits aggregation of misfolded proteins

The "PDIA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDIA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets